Down by a quarter in less than three months, is the CSL (ASX:CSL) share price a buy?

CSL shares have fallen heavily. Could it be a buy?

| More on:
A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares have fallen quite substantially in the last few months, declining by a quarter
  • It has dropped alongside many of the other ASX growth shares
  • CSL is seeing COVID problems, but is expecting these to lighten over time

The CSL Limited (ASX: CSL) share price has dropped by around 24% since 24 November 2021. Considering how large CSL is, that is a sizeable drop in market capitalisation terms.

Is this a great time to buy shares of the biotechnology company? Or is it now fair value?

What does the company actually do?

You aren't going to see the name CSL at the local shopping centre like you can with Commonwealth Bank of Australia (ASX: CBA), Woolworths Group Ltd (ASX: WOW) or Telstra Corporation Ltd (ASX: TLS).

CSL describes itself as a biotech leader. It operates in more than 35 countries and spends billions of dollars on research and development.

The company has more than 300 plasma collection centres across China, Europe and North America.

CSL's purpose is to help the health of people who have a range of serious and chronic medical conditions. It develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives.

What's happening to the CSL share price?

CSL shares are now lower than they were during the COVID-19 crash in 2020.

It has experienced a sizeable decline in the valuation as investor concerns rise regarding the rate of inflation and interest rates. Many other ASX growth shares have also seen sizeable declines including Xero Limited (ASX: XRO), WiseTech Global Ltd (ASX: WTC) and Altium Limited (ASX: ALU).

What is happening to CSL shares is not an isolated incident.

The broker Macquarie says that foot traffic is moderating for a sizeable portion of the plasma collection facilities. CSL said that US stimulus, stay-at-home orders and lockdowns caused FY21 plasma collection volume to be down by 20% compared to FY20. There are also increased collection costs.

The company opened 25 new centres in FY21. It was/is planning to open up to 40 new centres in FY22.

FY22 guidance

CSL is continuing to see demand for its main products, with expectations of strong demand for flu vaccines.

Plasma collection collections are expected to improve with CSL plasma initiatives and the COVID-19 vaccine roll-out.

The gross profit margin is expected to ease after increased plasma collection costs, partially offset by "modest" margin expansion due to growth in differentiated flu vaccines.

FY22 revenue is expected to grow by 2% to 5% at constant currency, whilst net profit after tax (NPAT) is expected to come between US$2.15 billion to US$2.25 billion at constant currency.

Is the CSL share price a buy idea?

Macquarie currently rates the healthcare ASX share as a buy, with a price target of $325. That implies a potential upside of more than 30%.

Based on the broker's estimates, the CSL share price is valued at 38x FY22's estimated earnings and 31x FY23's estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia owns and has recommended Telstra Corporation Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Opinions

Man sitting in a plane seat works on his laptop.
Opinions

Expert reveals 2 ASX stocks to sell — and 1 is a recent IPO

Toby Grimm from Baker Young shares his insights.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Opinions

Expert's verdict on 3 ASX 200 shares (2 have doubled in value and the other has lost 29%)

Two of these stocks were the best performers of their sectors in FY25. Should you buy, hold, or sell?

Read more »

A male investor sits at his desk pondering at his laptop screen with a piece of paper in his hand.
Opinions

Where I'd invest in ASX shares ahead of the likely RBA rate cut

These stocks look too good to miss.

Read more »

Person pretends to types on laptop drawn in sand.
Opinions

I sold one of my oldest ASX 200 shares last week. Here's why

Why would I sell one of my longest-held stocks?

Read more »

Broker analysing the share price.
Materials Shares

Buy, hold, or sell? Broker's verdict on 3 ASX 200 materials shares

Materials was one of four market sectors that weakened in overall value in FY25.

Read more »

A person sitting at a desk smiling and looking at a computer.
Technology Shares

3 ASX 200 tech shares to buy in July: Experts

The ASX tech sector delivered outstanding returns for investors in FY25.

Read more »

A group of executives sit in front of computer screens in a darkened room while a colleague stands giving a presentation with a share price graphic lit up on the wall
Opinions

2 ASX 200 large-cap shares that this fundie is cashing in after phenomenal growth

Shaw and Partners portfolio manager James Gerrish says he knows this will be an 'unpopular call'.

Read more »

Woman and man calculating a dividend yield.
Opinions

Buy or bail? Fundie's verdict on 2 ASX 300 shares

Stuart Bromley of Medallion Financial Group provides his insights.

Read more »